Skip to content

M-Vizion™ Macroscopic Radiographic Study

Medacta M-Vizion™ Macroscopic Radiographic Study, Multi-center, Post-Market Outcomes Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05721859
Enrollment
70
Registered
2023-02-10
Start date
2022-10-12
Completion date
2026-06-01
Last updated
2025-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Revision Hip Arthroplasty

Keywords

revision, hip, arthroplasty

Brief summary

Study of the patient's subsidence after revision hip arthroplasty by assessing gross stem subsidence in the femoral canal.

Detailed description

The aim of this study is to evaluate the M-Vizion modular stem performance in patients who undergo total hip replacement according to the standard practice. It is expected that subjects receiving revision hip arthroplasty with the Medacta M-Vizion™ modular hip stem will have less than 5mm of stem subsidence at 2 years.

Interventions

DEVICErevision hip arthroplasty

revision hip arthroplasty

Sponsors

Medacta USA
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Must be able to read, understand, and provide written informed consent on the Institutional Review Board (IRB) approved Informed Consent Form (ICF). * Ability to understand and provide written authorization for use and disclosure of personal health information. * Subjects who are able and willing to comply with the study protocol and follow-up visits. * Patients requiring a revision total hip replacement. * Subjects undergoing revision THA who will receive an M-Vizion femoral component according to the indications for use. * Male and female patients ages 21 - 80 years of age at the time of surgery.

Exclusion criteria

* Patients with neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device. * Patients with a systemic or metabolic disorder leading to progressive bone deterioration. * Patients bone stock is compromised by disease or infection, which could possibly prevent adequate support and/or fixation to the prosthesis. * Patients with an active or suspected latent infection in or about the hip joint. * Patients that are incarcerated.

Design outcomes

Primary

MeasureTime frameDescription
subsidence6 weeks post-op visit (± 2 weeks)Occurrence of subsidence \>5mm

Countries

United States

Contacts

Primary ContactEmily Hord, CCRP
ehord@medacta.us.com331-208-4284

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026